{
  "story_id": "409a5172fc48abd12be91201338ef004",
  "desk": "drm3",
  "revision": 1,
  "published_at": "2026-09-01T13:34:13.000Z",
  "content_hash": "360e45af06e57606a03a7ab4592bfb19ce22f4c8c66e51cd3227eea8d9e218ad",
  "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs",
  "basis": {
    "headline": "Alumis Stock Plunges 54% After Lupus Drug Trial Miss",
    "dek": "Alumis shares crashed 54.2% after its Phase 2b lupus trial failed to meet primary endpoints.",
    "prose": "Alumis stock plunged 54.2% in pre-open trading after the company announced that its Phase 2b LUMUS trial evaluating envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall trial population. [^1]\n\nPresident Trump announced on 2025-09-04 that his administration has made deals with nine new biotech companies regarding drug pricing. [^2]\n\nShares traded well below their previous close of $21.81 following the convergence of the trial miss, diluted subgroup path, prior insider selling activity, and a weak broader tape. [^3]\n\nThe announcement was released before the opening bell on September 1, accompanied by a brief trading halt pending the news. [^4]\n\nThe fact that IFNGS-high patients were under-represented in the overall LUMUS trial population was cited as the key reason headline response rates were diluted. [^5]\n\nAlumis said its experimental treatment for lupus failed to achieve the efficacy goals of a mid-stage clinical trial. [^6]\n\nThe nine new deals join the 17 agreements the administration previously struck with biotech companies. [^7]\n\nGSK is speeding up the development of its mRNA flu vaccine. [^8]",
    "cited": "[{\"statement\":\"Alumis stock plunged 54.2% in pre-open trading after the company announced that its Phase 2b LUMUS trial evaluating envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall trial population.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:05:57.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"President Trump announced on 2025-09-04 that his administration has made deals with nine new biotech companies regarding drug pricing.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:34:13.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"Shares traded well below their previous close of $21.81 following the convergence of the trial miss, diluted subgroup path, prior insider selling activity, and a weak broader tape.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:05:57.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"The announcement was released before the opening bell on September 1, accompanied by a brief trading halt pending the news.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:05:57.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"The fact that IFNGS-high patients were under-represented in the overall LUMUS trial population was cited as the key reason headline response rates were diluted.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:05:57.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Alumis said its experimental treatment for lupus failed to achieve the efficacy goals of a mid-stage clinical trial.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:34:13.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"The nine new deals join the 17 agreements the administration previously struck with biotech companies.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:34:13.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"GSK is speeding up the development of its mRNA flu vaccine.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-01T13:34:13.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]}]",
    "kind": "news"
  },
  "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature",
  "receipt": null,
  "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record",
  "generation_chain": {
    "wire": {
      "stream": "fountain_news",
      "story_id": "b85be0ea0f6c666a4a478fb980cc5257",
      "thread_id": "6757262fe830ed279b5eeaed977dca3e",
      "thread_label": "Alumis",
      "novelty": "UPDATE",
      "content_hash": "b8793c2bc5b02ad8334b4dfbb312fc982ee3a23b49a7b54bf78f4c110364a470",
      "last_published_at": "2026-09-01T13:34:13.000Z",
      "read_receipt": {
        "slice_hash": "7cc2cfeaa83a493f819c8993320c986b52ea8a4c8545b36b726e6545af56dd51",
        "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDFUMTM6MTU6NDMuMDAwMDAwWiIsImlkIjoiZWQ3YWM5NzJhYmIyODNmNGU4ZGZlYzNkNWE2MjI1MmYiLCJ2IjoiMSJ9",
        "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDFUMTM6NTk6MDkuMDAwMDAwWiIsImlkIjoiZjA1MmUxZjQ1NjYwMTY4NzA3Nzg2NDYyMzA2NDIzNWEiLCJ2IjoiMSJ9",
        "view": "v_fountain_news",
        "view_version": "1",
        "row_count": 100,
        "window_days": 3,
        "bytes_scanned": 12017721,
        "credits": 8,
        "price_per_100_rows": 8,
        "sig": "Tx-2k7FUXL9yhxRdwJcY-qYobOd77cCqgJGMy5gSwwA389Ny9iCT3Y-ihfvo1uzGXphQSnJrWjR6B4YuUg6sCQ",
        "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE",
        "signer_path": "lakehouse/data-extract/v1",
        "alg": "Ed25519",
        "signed": true
      }
    },
    "written_at": "2026-09-02T21:37:44.836Z"
  },
  "cited_facts": [
    {
      "statement": "Alumis stock plunged 54.2% in pre-open trading after the company announced that its Phase 2b LUMUS trial evaluating envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall trial population.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:05:57.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "President Trump announced on 2025-09-04 that his administration has made deals with nine new biotech companies regarding drug pricing.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:34:13.000Z",
      "publisher_count": 1,
      "sources": [
        "STAT"
      ]
    },
    {
      "statement": "Shares traded well below their previous close of $21.81 following the convergence of the trial miss, diluted subgroup path, prior insider selling activity, and a weak broader tape.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:05:57.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "The announcement was released before the opening bell on September 1, accompanied by a brief trading halt pending the news.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:05:57.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "The fact that IFNGS-high patients were under-represented in the overall LUMUS trial population was cited as the key reason headline response rates were diluted.",
      "source": "Investing.com",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:05:57.000Z",
      "publisher_count": 1,
      "sources": [
        "Investing.com"
      ]
    },
    {
      "statement": "Alumis said its experimental treatment for lupus failed to achieve the efficacy goals of a mid-stage clinical trial.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:34:13.000Z",
      "publisher_count": 1,
      "sources": [
        "STAT"
      ]
    },
    {
      "statement": "The nine new deals join the 17 agreements the administration previously struck with biotech companies.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:34:13.000Z",
      "publisher_count": 1,
      "sources": [
        "STAT"
      ]
    },
    {
      "statement": "GSK is speeding up the development of its mRNA flu vaccine.",
      "source": "STAT",
      "instrument": "News",
      "claim_key": null,
      "published_at": "2026-09-01T13:34:13.000Z",
      "publisher_count": 1,
      "sources": [
        "STAT"
      ]
    }
  ],
  "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true."
}